Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
Clinical trial NCT01273922 · COMPLETED
Trial details
- NCT number
- NCT01273922
- Sponsor
- NovaDigm Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-01-01
- Primary completion
- 2011-10-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.